Medication info
Neuropain Capsule 75 mg (Pregabalin)

Neuropain Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Unimed Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.
Packaging
30 capsules/bottle, 200 capsules/bottle
Approval status
Active

MFDS item code 201109291 · Approved 2011.10.31 · Insurance code 649506040

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. As this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. This drug is administered at a starting dose of 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week, based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. As the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Unimed Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It also helps as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not there are secondary generalized symptoms. Additionally, it is effective in relieving the symptoms of fibromyalgia. It is widely used for the treatment of various nerve-related diseases, improving patients' symptoms.

How to take

Adult dose

This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. As this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This drug may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. This drug is administered at a starting dose of 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week, based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. As the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so mood or behavioral changes should be carefully monitored during use. Do not take this medication if you have hypersensitivity to it or if you have genetic issues such as lactose intolerance. Diabetic patients may experience impacts on blood sugar control due to weight gain, so regular blood sugar monitoring and dose adjustment are necessary. If allergic reactions such as angioedema occur, immediately discontinue the medication and consult your healthcare provider. Elderly patients should be cautious of the risk of falls due to dizziness or drowsiness and should inform their healthcare provider of any changes in vision. Abruptly discontinuing this medication may trigger withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually tapered off according to a physician's instructions. Due to the potential for drug abuse or dependence, patients with a history of substance use should exercise particular caution and report any unusual behaviors immediately. Patients with impaired kidney function may need dose adjustments, and patients with heart disease should use it cautiously. Caution should also be exercised when combining this medication with opioid analgesics as it may enhance central nervous system depressant effects. It is advisable for pregnant women not to take this medication in early pregnancy due to potential effects on the fetus, and women of childbearing age should use effective contraception. During breastfeeding, since this medication may be passed into breast milk, the mother should discuss either discontinuing breastfeeding or discontinuing the medication with her doctor. This medication may cause dizziness and drowsiness, so it is advisable to avoid driving or operating hazardous machinery after taking it. Severe skin adverse reactions may occur rarely, so if any rashes or swelling develop, immediately discontinue use and consult a healthcare provider. In case of overdose, symptoms such as confusion, depression, or seizures may occur, and immediate medical attention should be sought.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinopharyngitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, directional disturbance, irritability, euphoria, decreased libido, depersonalization, hyperesthesia, restlessness, agitation, mood fluctuation, emotional blunting, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, ataxia, coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysphonia, dysesthesia, sensitivity reduction, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, dyskinesia, reflex reduction, motor disorders, psychomotor agitation, position-induced dizziness, sensory hypersensitivity, burning sensation, action tremor, syncope, confusion, motor retardation, olfactory disturbances, loss of taste, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field loss, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, during vibrations, changes in depth perception, strabismus, brightness in the visual field, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, homonymous bradycardia, homonymous tachycardia, homonymous arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, diaphoresis, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle twitching, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, feeling intoxicated, sensory abnormalities, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increase in alanine aminotransferase, increase in creatine phosphokinase, increase in aspartate aminotransferase, increased blood sugar, reduced platelet count, decreased potassium levels, weight loss, increased serum creatinine, reduced white blood cell count, hypersensitivity, allergic reactions, headaches, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme, delirium, paralysis (facial paralysis), affective disorder, agitation, restlessness, exacerbation of convulsions, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, bloody stools

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is best to maintain storage temperatures between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.

Package unit

30 capsules/bottle, 200 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.